189 related articles for article (PubMed ID: 36445624)
1. Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y
Mathew RO; Sidhu MS; Rihal CS; Lennon R; El-Hajjar M; Yager N; Lyubarova R; Abdul-Nour K; Weitz S; O'Cochlain DF; Murthy V; Levisay J; Marzo K; Graham J; Dzavik V; So D; Goodman S; Rosenberg YD; Pereira N; Farkouh ME
Cardiovasc Drugs Ther; 2024 Jun; 38(3):447-457. PubMed ID: 36445624
[TBL] [Abstract][Full Text] [Related]
2. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
[TBL] [Abstract][Full Text] [Related]
3. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
4. Genetic-Guided Oral P2Y
Ingraham BS; Farkouh ME; Lennon RJ; So D; Goodman SG; Geller N; Bae JH; Jeong MH; Baudhuin LM; Mathew V; Bell MR; Lerman A; Fu YP; Hasan A; Iturriaga E; Tanguay JF; Welsh RC; Rosenberg Y; Bailey K; Rihal C; Pereira NL
JACC Cardiovasc Interv; 2023 Apr; 16(7):816-825. PubMed ID: 37045502
[TBL] [Abstract][Full Text] [Related]
5. Safety of Dual-Antiplatelet Therapy After Myocardial Infarction Among Patients With Chronic Kidney Disease.
Rymer JA; Kaltenbach LA; Doll JA; Messenger JC; Peterson ED; Wang TY
J Am Heart Assoc; 2019 May; 8(10):e012236. PubMed ID: 31070112
[TBL] [Abstract][Full Text] [Related]
6. Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy.
Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Claassens DMF; Ten Berg JM; Asselbergs FW; Al-Ali AK
BMC Cardiovasc Disord; 2020 Jun; 20(1):268. PubMed ID: 32493215
[TBL] [Abstract][Full Text] [Related]
7. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W
Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798
[TBL] [Abstract][Full Text] [Related]
8. Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y
Xi Z; Wang Y; Lu Q; Qiu H; Gao Y; Gao A; Gao R
Thromb Res; 2023 Aug; 228():85-93. PubMed ID: 37301117
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
Wu Y; Zhou Y; Pan Y; Zhao X; Liu L; Wang D; Wang C; Li H; Johnston SC; Meng X; Wang Y; Wang Y;
Pharmacogenomics J; 2018 Dec; 18(6):713-720. PubMed ID: 29520080
[TBL] [Abstract][Full Text] [Related]
10. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
[TBL] [Abstract][Full Text] [Related]
11. A Genotype-Guided Strategy for Oral P2Y
Claassens DMF; Vos GJA; Bergmeijer TO; Hermanides RS; van 't Hof AWJ; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; Asselbergs FW; Mosterd A; Herrman JR; Dewilde WJM; Janssen PWA; Kelder JC; Postma MJ; de Boer A; Boersma C; Deneer VHM; Ten Berg JM
N Engl J Med; 2019 Oct; 381(17):1621-1631. PubMed ID: 31479209
[TBL] [Abstract][Full Text] [Related]
12. Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1-Year Results of the PENDULUM Registry.
Nakamura M; Kadota K; Takahashi A; Kanda J; Anzai H; Ishii Y; Shibata Y; Yasaka Y; Takamisawa I; Yamaguchi J; Takeda Y; Harada A; Motohashi T; Iijima R; Uemura S; Murakami Y;
J Am Heart Assoc; 2020 May; 9(10):e015439. PubMed ID: 32394794
[TBL] [Abstract][Full Text] [Related]
13. Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation.
Shimamatsu J; Sasaki KI; Katsuki Y; Kawasaki T; Murasato Y; Ajisaka H; Yokoi H; Tashiro H; Harada A; Hirakawa Y; Ishizaki Y; Ishimatsu T; Kagiyama K; Fukumoto Y; Kakuma T; Ueno T
Heart Vessels; 2020 Mar; 35(3):312-322. PubMed ID: 31549178
[TBL] [Abstract][Full Text] [Related]
14. Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Kim W; Kim JS; Rha SW; Choi BG; Jang WY; Kang DO; Park Y; Choi JY; Roh SY; Na JO; Choi CU; Kim EJ; Park CG; Seo HS; Choi SY; Byun JK; Cha J; Oh DJ; Jeong MH;
Heart Vessels; 2020 Sep; 35(9):1181-1192. PubMed ID: 32270356
[TBL] [Abstract][Full Text] [Related]
15. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
[TBL] [Abstract][Full Text] [Related]
16. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients).
Baber U; Li SX; Pinnelas R; Pocock SJ; Krucoff MW; Ariti C; Gibson CM; Steg PG; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Iakovou I; Dangas G; Aquino MB; Sartori S; Chieffo A; Moliterno DJ; Colombo A; Mehran R
Circ Cardiovasc Interv; 2018 Mar; 11(3):e006144. PubMed ID: 29870385
[TBL] [Abstract][Full Text] [Related]
17. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
Feng WH; Chang YC; Lin YH; Chen HL; Chang HM; Chu CS
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562942
[TBL] [Abstract][Full Text] [Related]
19. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
[TBL] [Abstract][Full Text] [Related]
20. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y
Sibbing D; Aradi D; Alexopoulos D; Ten Berg J; Bhatt DL; Bonello L; Collet JP; Cuisset T; Franchi F; Gross L; Gurbel P; Jeong YH; Mehran R; Moliterno DJ; Neumann FJ; Pereira NL; Price MJ; Sabatine MS; So DYF; Stone GW; Storey RF; Tantry U; Trenk D; Valgimigli M; Waksman R; Angiolillo DJ
JACC Cardiovasc Interv; 2019 Aug; 12(16):1521-1537. PubMed ID: 31202949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]